Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.61 - $1.96 $1,127 - $1,372
-700 Reduced 77.78%
200 $0
Q1 2023

May 15, 2023

SELL
$1.8 - $2.83 $1,440 - $2,264
-800 Reduced 47.06%
900 $1,000
Q4 2022

Feb 14, 2023

BUY
$2.05 - $5.5 $3,484 - $9,350
1,700 New
1,700 $4,000

Others Institutions Holding EQRX

About EQRx, Inc.


  • Ticker EQRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 448,140,992
  • Description
  • EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...
More about EQRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.